3WHO. Global status report on non-communicable diseases [ R ]. Geneva: 2011.
4WHO. Global atlas on cardiovascular disease prevention and control[ R]. Geneva: 2011.
5Mathers CD, Dejan L. Projections of global mortality and burden of disease from 2002 to 2030 [ J ]. PLoS Medicine, 2006,3 ( 11 ) : M42442. DOI: 10. 1371/journal. pmed. 0030442.
6Zhou Q, Liao JK. Pleiotropic effects of statins : basic research and clinical perspectives[ J]. Circ J, 2010,74 ( 5 ) : 818-826. DOI: 10. 1253/circj. CJ-10-0110.
7Wang CY, Liu PY, Liao JK, et al. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results [ J ]. Trends Mol Med, 2008,14( 1 ) :37-44. DOI: 10. 1016/j. molmed. 2007. 11. 004.
8Bonow RO, Mann DL, Zipes DP, et al. Braunwald's heart disease[M]. 9th edi6on. Philadelphia: Saunders Elsevier ,2012:987. Giannotti G, Landmesser U. Endothelial dysfunction as an early sign of atherosclerosis [ J ]. Herz, 2007,32 ( 7 ) : 568-572. DOI : 10. 1007/s00059-007-3073-1.
9Wojnicz R, Wilczek K, Nowalany-Kozielska E, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels [ J ]. 2006, 97 (6) :899-904. DOt: http ://dx. doi. org/10. 1016/j. amjcard. 2005.09. 142.
10Wassmann S, Laufs U, Biiumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species [ J ]. Hypertension, 2001,37 ( 6 ) : 1450-1457. DOI: 10. 1161/01. HYP. 37.6. 1450.
